
Breast Medical Oncologist @MountSinaiNYC @TischCancer
New York, NY
Joined February 2016
- Tweets29
- Following301
- Followers291
- Likes414
Rima Patel retweeted
.@eaonc is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below.
📅Feb 4 | 4 PM ET
🎙 @jsparano, @KalinskyKevin, @RimapatelMD
🔗bit.ly/EA1241webinar
Rima Patel retweeted
Trial Activation: EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. For more information: bit.ly/EA1241 cc: @KalinskyKevin, @RimapatelMD
Rima Patel retweeted
Adding everolimus to carboplatin in advanced #TNBC reduced the risk of disease progression or death by 52% vs carboplatin alone
By Amy Tiersten, MD, @RimapatelMD @IcahnMountSinai
ascopost.com/news/august-202…
#BCSM
#HCC #Immunotherapy
Rima Patel retweeted
📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in @JAMA_current
jamanetwork.com/journals/jam…
Excited to be staying at Mount Sinai as an Assistant Professor in Breast Medical Oncology! Thankful for the support of my incredible mentors, family, and friends. Looking forward to this next chapter!
.@RimapatelMD has joined our Hem/Onc faculty. Welcome!
linkedin.com/in/rima-patel-8…
icahn.mssm.edu/about/departm…
@IcahnMountSinai @DOMSinaiNYC
Rima Patel retweeted
Huge congratulations to @IcahnMountSinai @SinaiHemeOnc graduating fellows #2023 👏🎓🌟 Good luck on starting stellar careers!! – at Manhattan, NY
Rima Patel retweeted
Finally out in @NEJM results from #POSITIVE trial showing that temporary interruption of #EndocrineTherapy to attempt #pregnancy is safe in #BreastCancer patients: this is wonderful news…super congrats @AnnPartridgeMD @etop_ibcsg et al! @OncoAlert #bcsm
nejm.org/doi/full/10.1056/NE…
Thank you @OncLive for the opportunity to share our findings on the relationship between race, Ki67, and Oncotype as well as palliative care use in elderly patients with breast cancer.
Thank you, @RimapatelMD, of @MountSinaiNYC, for stopping by at #SABCS to talk about racial disparities and elderly palliative care in breast cancer! Check out our site for the latest insights from @SABCSSanAntonio! #bcsm
ow.ly/sQRH50LZ10S
Rima Patel retweeted
#VailWorkshop reunion at #SABCS2022 —great fun catching up friends/colleagues (missing a few in the 📸!) @AACR @ASCO @SABCSSanAntonio – at San Antonio, TX
Rima Patel retweeted
Our expert, @RimapatelMD will give poster presentations on her latest #BreastCancer research at #SABCS22. Be sure to visit her to learn more. Find out more about @SABCSSanAntonio: mshs.co/3Bawct2
@TischCancer
Rima Patel retweeted
End-of-summer fellows & faculty picnic in Central Park replete with food, games, sun and camaraderie!
👏🏼 to our wellness committee - @AzziJacques @RimapatelMD
@sridevirajeeve @BaileyFitz @orrinpail @RSJSheppard @XuejunWang @TischCancer @IcahnMountSinai – at Manhattan, NY
Rima Patel retweeted
Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain)
@OncoAlert @myESMO
Rima Patel retweeted
JUST IN: @GileadSciences announced statistically significant OS from Phase 3 TROPiCS-02: SG antibody-drug conjugate prolongs OS in heavily-pretreated patients with HR+/HER2- metastatic breast cancer
@DFCI_BreastOnc @OncoAlert, via @BusinessWire
businesswire.com/news/home/2…
Excited to share our work on the correlation between Oncotype and Ki67 using the IKWG categories. Important to consider when using Ki67 in clinical practice, especially to guide adjuvant abemaciclib @jsparano @MelanieKierMD @BZimmermanMD @TischCancer
The results of this study show no agreement between IHC-measured Ki67 using the International Ki67 Working Group prognostic groups & Oncotype DX Recurrence Score in patients with early #BreastCancer. acsjournals.onlinelibrary.wi… @TischCancer @RimapatelMD @jsparano @OncoAlert
Wrapping up an incredible week of clinical trial development at @AACR @ASCO #MCCR. Grateful to be have met and worked with these amazing oncologists! @quirogad @rleonferre @gandhi_shipra @FauziaRiaz @JingJiMD @JMcGuinnessMD @tarekmd91 @sridevirajeeve @lwumd323
Rima Patel retweeted
Representing @IcahnMountSinai @TischCancer @SinaiHemeOnc at the @AACR @ASCO #MCCR22 "Vail" workshop. What a phenomenal week learning to write robust clinical trials! 📝
📸: Vail faculty @KarynAGoodman; Attendees Jr faculty Jon Feld, cofellows @RimapatelMD, @lwumd323, @tarekmd91
Enjoying our last day in #Vail for the @AACR @ASCO #MCCR workshop with these amazing women oncologists! @sridevirajeeve @KrithikaShanm @PrincessMark17
Rima Patel retweeted
So proud of our PDG2 group @AACR @ASCO Vail #MCCR22 - Always an amazing experience, in an amazing place with amazing people 🫶. @oreganruth
Rima Patel retweeted
Beaming as I watch @laura_huppert present at #ASCO22 as a fellow! This is a big deal 🙌🏼
Rima Patel retweeted
.@RimapatelMD presented today at #ASCO22: Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score in early #breastcancer.
meetings.asco.org/abstracts-…
@MountSinaiNYC @IcahnMountSinai
















































